

EXPANDED AGENDA AND FACULTY!

Earn a
maximum of
26.75 AMA
PRA Category
1 Credits™.

36th Annual **CFS**[®] Chemotherapy Foundation SYMPOSIUM

Innovative Cancer Therapy for Tomorrow[®]



Announcing the Keynote Speaker:
Tiki Barber

NOVEMBER 7–9, 2018

New York Marriott Marquis
New York, NY

PROGRAM CO-CHAIRS:

Adam M. Brufsky, MD, PhD



Professor of Medicine
Associate Chief, Division of
Hematology/Oncology
Co-Director, Comprehensive Breast
Cancer Center
Director, Clinical Investigation
University of Pittsburgh
Pittsburgh, PA

Benjamin P. Levy, MD



Clinical Director of Medical
Oncology
Johns Hopkins Sidney Kimmel
Cancer Center
Sibley Memorial Hospital
Washington, D.C.

William K. Oh, MD



Chief, Division of Hematology
and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor
in Clinical Cancer Therapeutics
Icahn School of Medicine at
Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY

BENEFITS IN ATTENDING THIS YEAR'S CFS[®]!

- Network with the top minds in oncology
- Incorporate the latest clinical data into your practice
- Challenge the experts with your most difficult cases
- 100 Experts. 25 Tumor Types. 3 Days. 1 Meeting.

For more information and registration, visit us at
gotoper.com/go/CFS18BRO



OVERVIEW

Each year, the **Chemotherapy Foundation Symposium® (CFS®)**, brings together more than 1,000 healthcare professionals for 3 days, with one goal in mind: promoting evidence-based science into state-of-the-art cancer care.

At this year's *36th Annual CFS®*, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics.

Join us in November for **Innovative Cancer Therapy for Tomorrow®!**

REGISTRATION FEES	ADVANCED	ON-SITE
Physicians	\$599	\$699
Fellows*	\$249	\$349
Nurses, PAs, Other Healthcare Professionals	\$249	\$349
Industry**	\$749	\$849

***FELLOWS** registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

****INDUSTRY** is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

TWO WAYS TO REGISTER



Online

gotoper.com/go/CFS18BRO

or



Call

1-609-378-3701

For any other question email us at:
info@gotoper.com

ANNOUNCING THE KEYNOTE SPEAKER: TIKI BARBER



Best known for his time on the field, former New York Giants football player Tiki Barber serves as co-host of CBS Sports Radio's "Tiki & Tierney". Barber is one of three NFL players in football history with more than 10,000 career rushing yards and 5,000 career yards receiving.

Tiki was 22 and playing for the University of Virginia Cavaliers when his mother was diagnosed with breast cancer. Initially keeping her diagnosis a secret, Tiki's mother fought through several forms of therapy and came out on top. She's now been in remission for two decades. Today Tiki tells her motivational story to raise awareness and help others through the same journey his family endured.



AGENDA

Wednesday, November 7, 2018

6:00 AM	Breakfast (Exhibit Hall)	
6:55 AM	Welcome and Introductions	
Hematology		
Myeloproliferative Neoplasms/Myelodysplastic Syndrome		
7:00 AM	Evaluating the Integration of JAK Inhibition Strategies for the Management of PV	Srdan Verstovsek, MD, PhD
7:15 AM	Second-Line Therapy After JAK Inhibition in MF	Marina Kremyanskaya, MD, PhD
7:30 AM	What Should You Do If Azacitidine Is No Longer Working for Your Patient With MDS?	Azra Raza, MD
Chronic Lymphocytic Leukemia		
7:45 AM	CLL: Novel Agents, Novel Combinations	Richard R. Furman, MD
8:00 AM	Medical Crossfire® : Chemotherapy Versus Novel Agents in Modern Management of CLL	George P. Canellos, MD
Lymphoma		
8:20 AM	TBA	TBA
8:35 AM	Checkpoint Immunotherapy in Lymphoma: Present and Future	Joshua Brody, MD
8:50 AM	Assessment of Evolving Targeted Strategies in Follicular Lymphoma	John P. Leonard, MD
Leukemias		
9:05 AM	Novel Immune-Based Therapies for AML	Naval G. Daver, MD
9:20 AM	Targeted Therapies for AML	Alexander Perl, MD
9:35 AM	Optimizing Outcomes in ALL: Assessment of State-of-the-Art Strategies and Proactive Toxicity Management	Elias Jabbour, MD
9:50 AM	Key Sequencing Considerations in CML Treatment	Michael J. Mauro, MD
CAR T Focus		
10:05 AM	Assessing Pivotal Data Sets With the Use of CAR T Therapies	Anas Younes, MD
10:20 AM	Practical Applications and Considerations for CAR T: Optimizing Use in the Clinic	TBA
10:40 AM	Break (Exhibit Hall)	
Multiple Myeloma		Moderator: Ajai Chari, MD
11:10 AM	Frontline Therapy for Multiple Myeloma in 2018	Brian G.M. Durie, MD
11:25 AM	Current Role of Minimal Residual Disease Testing in Multiple Myeloma	C. Ola Landgren, MD, PhD
11:40 AM	Novel Therapies in Relapsed/Refractory Multiple Myeloma	Ajai Chari, MD
Rare Hematologic Malignancies		
11:55 AM	Key Considerations: When and How to Treat Patients With Waldenström Macroglobulinemia	Steven Treon, MD, PhD
12:10 PM	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Novel Targeted Therapies in a Rare Cancer	Naveen Pemmaraju, MD
12:25 PM	Non-CME Lunch Symposia - lunch provided	
Sarcoma		
1:40 PM	Key Concepts in the Diagnosis and Treatment of Soft-Tissue Sarcomas	Andrew J. Wagner, MD, PhD
Genitourinary Cancers		Moderator: William K. Oh, MD
1:55 PM	Immunotherapeutic Strategies and How They Are Changing the Trajectory of RCC Treatment Planning	Toni K. Choueiri, MD
2:10 PM	The Mechanistic Rationale for the Application of Targeted Sequencing Strategies for Advanced RCC	Robert A. Figlin, MD, FACP
2:25 PM	Targeting Treatment Resistance in CRPC	David R. Wise, MD, PhD
2:40 PM	Management of M0 CRPC: Enzalutamide, Apalutamide, or Nothing?	Maha Hussain, MD, FACP, FASCO
2:55 PM	Break (Exhibit Hall)	
3:25 PM	Oligometastatic Disease: Novel Imaging and the Role of Local Therapy	Michael J. Zelefsky, MD
3:40 PM	Immunotherapy and Targeted Agents in Prostate Cancer	Ravi A. Madan, MD
3:55 PM	Immunotherapy in Bladder Cancer	Petros Grivas, MD, PhD
4:10 PM	What to Do After Checkpoint Inhibitor Failure: Emerging Agents and Combinations	Arjun V. Balar, MD
4:25 PM	Medical Crossfire® : Targeted Therapy, Immunotherapy, and Chemotherapy for Advanced Bladder Cancer: What Is the Right Treatment? What Is the Right Sequence?	Moderator: William K. Oh, MD Arjun V. Balar, MD; Gopakumar V. Iyer, MD; Petros Grivas, MD, PhD; Matthew Galsky, MD
4:45 PM	GU Panel and Audience Q&A	GU Faculty
5:00 PM	Adjourn	
5:00 PM - 6:00 PM	Welcome Reception (Exhibit Hall)	

Nursing Track - Wednesday

5:00 PM	Welcome	
5:05 PM	Pathology 101: Reading and Understanding the Pathology Report	Ann Culkin, RN, OCN®
5:25 PM	Clinical Pearls in Managing Immune-Mediated Toxicities	Massey Nematollahi, RN, MScN, OCN®, CON(C)
5:45 PM	Latest Practices in Lymphedema	Julie Pederson, BSW, RN, OCN®, CBCN
6:05 PM	Hematology: Integrating New Therapies Into Practice	Beth Faiman, PhD, CNP
6:25 PM	Q&A	Panel
6:35 PM	Break	
6:55 PM	The Importance of Tobacco Control in Oncology: A Nursing Perspective	Linda Sarna, PhD, RN, FAAN
7:15 PM	Navigating Patients Through Cancer	Kathleen A. Gamblin, RN, BSN, OCN
7:35 PM	The Latest and Greatest in Breast Cancer	TBA
7:55 PM	Sexuality After Cancer: The Nurse's Role	Anne Katz, PhD, RN, FAAN
8:15 PM	Panel and Audience Q&A	Panel
8:25 PM	Adjourn	

Thursday, November 8, 2018

6:00 AM	Breakfast (Exhibit Hall)	
6:55 AM	Welcome	
Gynecologic Oncology		Moderator: Susana M. Campos, MD, MPH
7:00 AM	PARP Inhibitors: Combinatorial Therapy	Maurie Markman, MD
7:15 AM	The Role of Immunotherapy in Gynecological Cancer	Patrick Ott, MD, PhD
7:30 AM	Novel Therapies and Roles for Current Agents in Ovarian Cancer (non-PARP, non-IO)	Bradley J. Monk, MD, FACS, FACOG
7:45 AM	Advances in the Management of Cervical Cancer	Gini Fleming, MD
8:00 AM	Gynecologic Cancers: The Impact of BRCA (Dys) Function on Biology and Treatment	Franco M. Muggia, MD
8:15 AM	Medical Crossfire® : Chemotherapy Improves Outcomes in Patients with Early-Stage, High-Risk Uterine Cancer	Moderator: Susana M. Campos, MD, MPH Angeles Alvarez Secord, MD
Dermatologic Cancers		Moderator: Jason J. Luke, MD, FACP
8:35 AM	Current Sequences and Future Triples in Melanoma	Geoffrey T. Gibney, MD
8:50 AM	Up-to-Date Adjuvant Therapy in Melanoma	Hussein Tawbi, MD, PhD
9:05 AM	Clinical Trial Updates in the Treatment of Advanced Cutaneous Squamous-Cell Carcinoma	Anna C. Pavlick, BSN, MS, DO, MBA
9:20 AM	Medical Crossfire® : Which Immunotherapy Should You Choose?	Moderator: Jason J. Luke, MD, FACP Hussein Tawbi, MD, PhD
2018 Update: Science of Immunotherapy		Moderator: Jason J. Luke, MD, FACP
9:40 AM	The Intersection Between Genomics and Immunotherapy	Nadeem Riaz, MD, MSc
9:55 AM	Immune Checkpoint Blockade-Based Combination Therapies	Jason J. Luke, MD
10:10 AM	Biomarkers for Immunotherapy	TBA
10:25 AM	Optimizing Outcomes Through Improved Immunotherapy-Related Adverse Event Management	Richard D. Carvajal, MD
10:40 AM	Break (Exhibit Hall)	
Keynote Lectures		
11:10 AM	Giants of Cancer Care Lecture...Focus on Pediatric Oncology	TBA
11:30 AM	Greenspan Lecture and Q&A	TBA
12:00 PM	Keynote Presentation Introduction	Phil Talamo, CHCP
12:05 PM	Keynote Presentation and Q&A	Tiki Barber
12:45 PM	Non-CME Lunch Symposia - lunch provided	
Breast Cancer		Moderator: Adam M. Brufsky, MD, PhD
2:00 PM	Molecularly Guided Management of Breast Cancer	Joseph A. Sparano, MD
2:15 PM	Putting PARP Inhibitors Into Practice in Breast Cancer	Mark E. Robson, MD
2:30 PM	Management of HER2+ Disease: Optimal Regimens, Optimal Durations	Chau T. Dang, MD
2:45 PM	State-of-the-Art Neoadjuvant Approaches in Breast Cancer	Adam M. Brufsky, MD, PhD
3:00 PM	Break (Exhibit Hall)	
3:30 PM	Adjuvant Therapy for ER+ Breast Cancer	TBA
3:45 PM	Medical Crossfire® : LHRH Preserves Fertility in Premenopausal Women With Early Breast Cancer	Moderator: Adam Brufsky, MD, PhD PRO: TBA CON: Kutluk Oktay, MD, PhD
4:05 PM	Assisted Reproductive Technology for Women Seeking Fertility Preservation	Kutluk H. Oktay, MD, PhD
4:20 PM	CDK4/6 Inhibitors: A Practice Update	Joyce A. O'Shaughnessy, MD

4:35 PM	What's New in Immunotherapy for Breast Cancer?	Heather L. McArthur, MD, MPH
4:50 PM	Breast Panel and Audience Q&A	Breast Cancer Faculty
5:05 PM	Adjourn	

"How I Do It" Track - Thursday

5:00 PM	Welcome	
5:05 PM	How I Use Bone-Modifying Agents in the Metastatic Setting	Catherine Van Poznak, MD, FASCO
5:35 PM	How I Manage Immunotherapy-Related Adverse Events	Bryan J. Schneider, MD
6:05 PM	How I Treat High-Risk Myelofibrosis- and MPN-Related AML	John O. Mascarenhas, MD
6:35 PM	Break	
6:55 PM	How Do I Select First-Line Therapy in RCC?	TBA
7:25 PM	How I Treat Locally Advanced Rectal Cancer	Christopher Lieu, MD
7:55 PM	How I Choose Between Single-Agent Anti-PD-1 Therapy or Anti-PD-1/CTLA4 Combination Therapy	Adil I. Daud, MD
8:25 PM	How I Treat Early Relapsing Follicular Lymphoma	Peter Martin, MD
8:55 PM	Adjourn	

Friday, November 9, 2018

6:00 AM	Breakfast (Exhibit Hall)	
6:55 AM	Welcome	
Lung Cancers		
7:00 AM	The Treatment-Naïve Patient Without an Actionable Mutation: Navigating the New Regimens	Hossein Borghaei, MS, DO
7:15 AM	Optimal Management for Patients With Advanced Squamous NSCLC	Mark A. Socinski, MD
7:30 AM	Novel Immunotherapy Combination Strategies in NSCLC	Roy S. Herbst, MD, PhD
7:45 AM	Leading to Cure: Incorporating Immunotherapy and Targeted Therapy in Earlier-Stage Disease	Balazs Halmos, MD
8:00 AM	Multimodality Therapy	Shirish M. Gadgeel, MD
8:15 AM	ALK-Directed Therapies: How Should We Sequence?	D. Ross Camidge, MD, PhD
8:30 AM	EGFR-Mutant Lung Cancer: Frontline Strategies and Beyond	Sarah B. Goldberg, MD, MPH
8:45 AM	The More, the Merrier: Expanding Array of Oncogenic Drivers (including BRAF, MET, NTRK, RET, and ROS1)	Alexander E. Drilon, MD
9:00 AM	Plasma Genotyping in NSCLC: How to Use Liquid Biopsies Along the NSCLC Treatment Continuum	Joshua Bauml, MD
9:15 AM	New Treatment Approaches for Small Cell Lung Cancer	Roman Perez-Soler, MD
9:30 AM	Antiangiogenesis in Lung Cancer: Can It Survive in the World of IO Therapy?	Mark G. Kris, MD
9:45 AM	Emerging Treatment Options for Mesothelioma and Thymoma	Stephen V. Liu, MD
10:00 AM	Medical Crossfire®: Which Biomarker Is Best to Guide Clinical Decision Making With IO Therapy? PD-L1, TMB, or Nothing at All?	Moderator: Benjamin P. Levy, MD; Mark A. Socinski, MD; Hossein Borghei, DO, MS; Sarah B. Goldberg, MD, MPH; Roy S. Herbst, MD, PhD
10:20 AM	Break (Exhibit Hall)	
Gastrointestinal Cancers		Moderator: Cathy Eng, MD
10:50 AM	Individualizing Therapy for Gastric Cancer	David H. Ilson, MD, PhD
11:05 AM	With Many Emerging Options, How Will We Sequence Therapies for Hepatocellular Carcinoma?	Anthony B. El-Khoueiry, MD
11:20 AM	New Multidisciplinary Treatment Opportunities in an Era of Expanding Treatment Options	Ghassan K. Abou-Alfa, MD, MBA
11:35 AM	Pancreas Cancer: Locally Advanced, Unresectable Pancreatic Cancer	Eileen M. O'Reilly, MD
11:50 AM	Key Sequencing Considerations in the Management of Advanced Colorectal Cancer	Jordan Berlin, MD
12:05 PM	Evolving Targeted and Immunotherapeutic Options for Colorectal Cancer	Cathy Eng, MD, FACP
12:20 PM	Evaluating Evolving Approaches and Combinations in the Management of Neuroendocrine Tumors	Diane Reidy Lugones, MD
12:35 PM	Medical Crossfire®: The MSI Story in GI and Lessons Translated Pan-Tumor	Moderator: Cathy Eng, MD FACP
12:55 PM	Non-CME Lunch Symposia - lunch provided	
Glioblastoma Multiforme		
2:10 PM	Clinical Trial Update: Immunotherapy Strategies and Their Application in GBM	David A. Reardon, MD
2:25 PM	Key Evidence on the Use of Tumor-Treating Fields for GBM Management	Rimas V. Lukas, MD
2:40 PM	TBA	TBA

Head, Neck, Thyroid Cancers		
2:55 PM	Recent Advances in the Management of Head and Neck Squamous Cell Carcinoma	Robert L. Ferris, MD, PhD
3:10 PM	Immunotherapeutic and Targeted Approaches: Evolving Roles in the Management of Thyroid Cancer	Marcia Simpson Brose, MD, PhD
3:25 PM	Break	
Patient-Centered Care and Oncology Practice		
3:50 PM	Key Concepts to Maximize the Prevention and Treatment of CINV	Richard J. Gralla, MD, FACP
4:05 PM	Addressing the Opioid Epidemic with Effective Postoperative Pain Management Strategies	Patrick I. Borgen, MD
4:20 PM	Novel Strategies to Manage Neutropenia and Optimize Outcomes in Cancer Care	Jeffrey Crawford, MD
4:35 PM	Oncology Practice, Research, and Patient Engagement in the Digital Health Age	Edward P. Ambinder, MD
4:50 PM	Closing Remarks	
4:55 PM	Adjourn	

Agenda accurate at time of printing.

COMMITTEE MEMBERS

Arjun V. Balar, MD

Perlmutter Cancer Center, NYU Langone
New York, NY

Susana M. Campos, MD, MPH

Dana-Farber Cancer Institute
Boston, MA

Ajai Chari, MD

The Mount Sinai Hospital
New York, NY

Alexander E. Drilon, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Cathy Eng, MD, FACP

The University of Texas MD Anderson
Cancer Center
Houston, TX

Jason J. Luke, MD, FACP

The University of Chicago Medicine
Chicago, IL

John Mascarenhas, MD

Icahn School of Medicine at Mount Sinai
New York, NY

FACULTY

Ghassan K. Abou-Alfa, MD, MBA

Memorial Sloan Kettering Cancer Center
New York, NY

Edward P. Ambinder, MD

Icahn School of Medicine at Mount Sinai
New York, NY

Joshua Bauml, MD

University of Pennsylvania
Philadelphia, PA

Jordan Berlin, MD

Vanderbilt-Ingram Cancer Center
Nashville, TN

Patrick I. Borgen, MD

Brooklyn Breast Cancer Program
Brooklyn, NY

Hossein Borghaei, MS, DO

Fox Chase Cancer Center
Philadelphia, PA

Joshua Brody, MD

Hess Center for Science and Medicine
New York, NY

Marcia Simpson Brose, MD, PhD

Hospital of the University of Pennsylvania
Philadelphia, PA

D. Ross Camidge, MD, PhD

University of Colorado Denver School
of Medicine
Denver, CO

George P. Canellos, MD

Dana-Farber Cancer Institute
Boston, MA

Richard D. Carvajal, MD

Columbia University Medical Center
New York, NY

Toni K. Choueiri, MD

Harvard Medical School
Boston, MA

Jeffrey Crawford, MD

Duke Cancer Institute
Durham, NC

Ann Culkin, RN, OCN®

Memorial Sloan Kettering Cancer Center
Middletown, NJ

Chau T. Dang, MD

Memorial Sloan Kettering Cancer Center
West Harrison, NY

Adil I. Daud, MD

UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, CA

Naval G. Daver, MD

The University of Texas MD Anderson
Cancer Center
Houston, TX

Brian G.M. Durie, MD

Cedars-Sinai Outpatient Cancer Center
Los Angeles, CA

Anthony B. El-Khoueiry, MD

University of Southern California
Los Angeles, CA

Beth Faiman, PhD, CNP

Cleveland Clinic
Cleveland, OH

Robert L. Ferris, MD, PhD

University of Pittsburgh Cancer Institute
Pittsburgh, PA

Robert A. Figlin, MD, FACP

Cedars-Sinai Medical Center
Los Angeles, CA

Gini Fleming, MD

The University of Chicago Medicine
Chicago, IL

Richard R. Furman, MD

Weill Cornell Medical College
New York, NY

Shirish M. Gadgil, MD

University of Michigan
Ann Arbor, MI

Matthew Galsky, MD

Icahn School of Medicine at Mount Sinai
New York, NY

FACULTY

A. Gamblin, RN, BSN, OCN

Varian Medical Systems
Atlanta, GA

Geoffrey T. Gibney, MD

George-Lombardi Comprehensive
Cancer Center
Chevy Chase, MD

Sarah B. Goldberg, MD, MPH

Yale School of Medicine/Yale Cancer Center
New Haven, CT

Richard J. Gralla, MD, FACP

Albert Einstein College of Medicine
Bronx, NY

Petros Grivas, MD, PhD

University of Washington Medical Center
Seattle, WA

Balazs Halmos, MD

Albert Einstein College of Medicine/
Montefiore Medical Center
Bronx, NY

Roy S. Herbst, MD, PhD

Yale Cancer Center, Smilow Cancer Hospital
New Haven, CT

Maha H. Hussain, MD, FACP, FASCO

Northwestern University Feinberg School
of Medicine
Chicago, IL

David H. Ilson, MD, PhD

Weill Cornell Medical College
New York, NY

Gopakumar V. Iyer, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Elias Jabbour, MD

The University of Texas MD Anderson
Cancer Center
Houston, TX

Anne Katz, PhD, RN, FAAN

CancerCare Manitoba
Winnipeg, Manitoba, Canada

Marina Kremyanskaya, MD, PhD

The Mount Sinai Hospital
New York, NY

Mark G. Kris, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Matteo Lambertini, MD

Institut Jules Bordet
Brussels, Belgium

C. Ola Landgren, MD, PhD

Memorial Sloan Kettering Cancer Center
New York, NY

John P. Leonard, MD

Weill Cornell Medicine and New York-
Presbyterian Hospital
New York, NY

Christopher Lieu, MD

University of Colorado Anschutz
Medical Campus
Aurora, CO

Stephen V. Liu, MD

Georgetown University Medical Center
Washington, D.C.

Rimas V. Lukas, MD

Northwestern University
Chicago, IL

Ravi A. Madan, MD

National Cancer Institute
Bethesda, MD

Maurie Markman, MD

Drexel University College of Medicine
Philadelphia, PA

Peter Martin, MD

Weill Cornell Medicine
New York, NY

Michael J. Mauro, MD

Weill Cornell Medical College
New York, NY

Heather L. McArthur, MD, MPH

Cedars-Sinai Medical Center
Los Angeles, CA

Bradley J. Monk, MD, FACS, FACOG

US Oncology Research Network -
Gynecologic Program
Phoenix, AZ

Franco M. Muggia, MD

NYU Langone Medical Center
New York, NY

**Massey Nematollahi, RN, MScN, OCN®,
CON®**

Stronach Regional Cancer Center at
Southlake Regional Health Center
Ontario, Canada

Eileen M. O'Reilly, MD

Weill Cornell Medical College
New York, NY

Kutluk Oktay, MD, PhD

Yale University School of Medicine
New Haven, CT

Joyce A. O'Shaughnessy, MD

The US Oncology Network
Dallas, TX

Patrick Ott, MD, PhD

Harvard Medical School
Boston, MA

Jae H. Park, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Anna C. Pavlick, BSN, MS, DO, MBA

NYU Medical Oncology Associates
New York, NY

Julie Pederson, BSW, RN, OCN, CBCN

Baylor Scott & White McClinton
Cancer Center
Waco, TX

Naveen Pemmaraju, MD

MD Anderson Cancer Center
Houston, TX

Roman Perez-Soler, MD

Albert Einstein College of Medicine
Bronx, NY

Alexander Perl, MD

University of Pennsylvania
Philadelphia, PA

Azra Raza, MD

Columbia University Medical Center
New York, NY

Diane Reidy Lagunes, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Nadeem Riaz, MD, MSc

Memorial Sloan Kettering Cancer Center
New York, NY

Mark E. Robson, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Linda Sarna, PhD, RN, FAAN

UCLA School of Nursing
Los Angeles, CA

Bryan J. Schneider, MD

University of Michigan
Ann Arbor, MI

Angeles Alvarez Secord, MD

Duke Cancer Institute
Durham, NC

Mark A. Socinski, MD

Florida Hospital Cancer Institute
Orlando, FL

Joseph A. Sparano, MD

Montefiore Medical Center
Bronx, NY

Hussein Tawbi, MD, PhD

UT MD Anderson Cancer Center
Houston, TX

Steven Treon, MD, PhD

Harvard Medical School
Boston, MA

Catherine Van Poznak, MD, FASCO

University of Michigan
Ann Arbor, MI

Srdan Verstovsek, MD, PhD

MD Anderson Cancer Center
Houston, TX

Andrew J. Wagner, MD, PhD

Dana-Farber Cancer Institute
Boston, MA

David R. Wise, MD, PhD

NYU Langone Health
New York, NY

Anas Younes, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Michael J. Zelefsky, MD

Weill-Cornell Medical School
New York, NY

Faculty accurate at time of printing.





2 Clarke Drive, Suite 110
Cranbury, NJ 08512

Phone: +1 (888) 949-0045
Email: info@gotoper.com

“ I COME TO CFS TO
GATHER INFORMATIVE
INFORMATION THAT WILL
HELP ME PROVIDE GREAT
PATIENT CARE. ”

STAY AROUND FOR SATURDAY

13th Annual New York LUNG CANCERS SYMPOSIUM

SATURDAY, NOVEMBER 10, 2018
New York Marriott Marquis
1535 Broadway | New York, NY 10036

Learn more at: gotoper.com/go/NYL18CFS

DIRECTIONS IN

Oncology Pharmacy

Saturday, November 10, 2018
CROWNE PLAZA TIMES SQUARE • NEW YORK, NEW YORK

Learn more at: gotoper.com/go/DIOPNYC

ACCREDITATION/CREDIT DESIGNATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 26.75 Contact Hours.



Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is approved for a maximum of 22.75 contact hours under the ACPE universal activity numbers:

November 7, 2018, Conference Day 1 – 0290-9999-18-099-L01-P (7.75 contact hours)

November 8, 2018, Conference Day 2 – 0290-9999-18-100-L01-P (7.0 contact hours)

November 9, 2018, Conference Day 3 – 0290-9999-18-101-L01-P (8.0 contact hours)

The activity is available for continuing education (CE) credit through December 9, 2018.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer, Pharmacyclis LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., and Taiho Oncology, Inc.

For more information and registration, visit us at
gotoper.com/go/CFS18BRO